NCT02339038View on ClinicalTrials.gov

Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia

PHASE4CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

January 7, 2015

Primary Completion Date

June 15, 2016

Study Completion Date

July 13, 2018

Conditions
HCV HIV
Interventions
DRUG

Ledipasvir 90 mg and Sofosbuvir 400 mg

Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination as per standard of care treatment guidelines

Trial Locations (2)

20002

Unity Health Care, Inc./DC General, Washington D.C.

20020

Family Medical and Conseling Services, Washington D.C.

All Listed Sponsors
lead

National Institutes of Health Clinical Center (CC)

NIH

NCT02339038 - Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia | Biotech Hunter | Biotech Hunter